The latest study by the Association for Accessible Medicines has found that “persistent design flaws within Medicare Part D act as barriers to coverage of and access to recently approved, low-cost generic drugs.” Commenting on the findings of the study – named “New Generics Are Less Available in Medicare Than Commercial Plans” – Christine Simmon, senior vice president for policy and strategic alliances at the AAM, said “there’s simply no justification for providing America’s seniors worse access to lower-cost generics than beneficiaries in commercial health plans receive.”
Though the Medicare part D drug program was designed to ensure that seniors have affordable access to lifesaving medicines, Simmon...
